Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03649724 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary endpoints: details revised at 1 of 1 entryShow 5 more changesShow less
Trial completed
Final enrollment: 86 participants (planned 180)
Eligibility criteria expanded, about 14 words
Secondary endpoints: details revised at 3 of 6 entries
Publications: details revised at 4 of 4 entries
MinorPrimary and study completion dates: Jul 1, 2026 to Jul 25, 2026v19
MinorTrial status: Recruiting to Active, Not Recruiting
Primary and study completion dates: Aug 1, 2026 to Jul 1, 2026
Site details revised at 3 of 3 sites
v18
MinorPrimary and study completion dates: May 2026 to Aug 1, 2026v17
MinorPrimary completion date: Dec 2025 to May 2026
Study completion date: Feb 2026 to May 2026
Site contacts updated at 3 of 3 sites
Publications: 3 to 4
v16
Show 14 earlier versionsHide 14 earlier versions
NotablePrimary completion date: Feb 2025 to Dec 2025
Eligibility criteria shortened, about 24 words
v15
MinorEligibility criteria shortened, about 37 wordsv14
MinorSite details revised at 2 of 3 sitesv13
MinorSite details revised at 1 of 3 sitesv12
MinorSite contacts updated at 1 of 3 sitesv11
MinorRe-verified, no change to tracked fieldsv10
MinorSite contacts updated at 1 of 3 sitesv9
MinorStart date changed from estimate of Dec 2020 to Nov 27, 2020v8Show 4 more changesShow less
Eligibility criteria expanded, about 11 words
Site contacts updated at 1 of 3 sites
Collaborators: 1 to 2
Study description shortened, about 1 word
NotableStart date: Sep 2020 to Dec 2020v7
NotableStart date: Jun 2020 to Sep 2020v6
NotableStart date: Feb 2020 to Jun 2020v5
NotableTrial status: Not Yet Recruiting to Recruitingv4Show 8 more changesShow less
Enrollment target: 50 to 180
Primary endpoint revised
Study sites: 1 to 3
Interventions: LUPRON DEPOT 22.5 mg (Drug), Placebo (Drug) to Eligard 22.5Mg Suspension for Injection (Drug), Placebo (Drug)
Eligibility criteria shortened, about 33 words
Secondary endpoints expanded, about 60 words
Study description expanded, about 170 words
Study title revised
NotableLead sponsor: NYU Langone Health to Weill Medical College of Cornell Universityv3Show 6 more changesShow less
Primary completion date: Dec 2020 to Feb 2025
Start date: Dec 2018 to Feb 2020
Study completion date: Dec 2020 to Feb 2026
Eligibility criteria revised
Study site revised
Collaborators expanded, about 5 words
MinorRe-verified, no change to tracked fieldsv2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The LUCINDA Trial is a three-site, phase II, randomized, double-blind, placebo-controlled study of leuprolide acetate (Eligard) in women with Mild Cognitive Impairment or Alzheimer's Disease taking a stable dose of a cholinesterase inhibitor medication like donepezil. Its objective is to assess the efficacy of a 48-week regimen of leuprolide (22.5 mg per 12 weeks) compared to placebo on cognitive function, global function and plasma and neuroimaging biomarkers.